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The prevalent ages at onset for Kawasaki Disease (KD) and
Epstein-Barr virus (EBV) infection are known to be similar in
Korea and Japan. We evaluated the correlation between EBV
infection and KD. The antibodies to EBV such as anti-viral
capsid antigen (VCA) IgG and IgM, anti-diffuse and restricted
early antigen IgG (anti-EADR IgG), and the anti-EBV deter-
mined nuclear antigen IgG (anti-EBNA IgG) were examined
in 29 KD patients at five separate times sequentially during
a period of one year, and also in 14 other children with a past
history of KD. The results of each group were compared with
those of age-matched controls. The positive rates of anti-VCA
IgG and IgM at presentation in the KD patients were 41.4%
(12/29) and 0% (0/29), respectively. Only one patient was
found to be anti-VCA IgM-positive within two months. There
were no cases of anti-VCA IgG except one, anti-EADR IgG
and anti-EBNA IgG positive to negative seroconversion during
the year. The children with a past history of KD showed higher
anti-EBNA IgG-positive rates than the controls (p = 0.04).
There was no difference in the seropositive rates of the anti-
bodies to EBV, cytomegalovirus, herpes simplex virus and
herpes zoster virus. In conclusion, children with KD were
noted to have normal immune responses to EBV infection.
Children with a past history of KD seemed to be infected with
EBV at a later age than children with no history of KD.
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INTRODUCTION
Kawasaki Disease (KD) is an acute multisystem
vasculitis with an unknown etiology that afflicts
mostly young children.
1 Clinical and epidemiolo-
gical studies have suggested that KD is closely
related to an infectious disease.
2,3 The acute onset
of a self-limiting course, the prevalent population
(rare in children < 6 months and > 5 years of
age) and the existence of clusters or epidemics
with a wave-like spread all suggest that KD is
related to infectious agents, particularly those of
a viral origin. The recent incidence of KD in Korea
is approximately 90 per 100,000 children younger
than five years of age. This is similar to that of
Japan because of the geographic, racial and envi-
ronmental similarities between the two countries.
4
The recurrence rate of KD is known to be approxi-
mately 2-3%.
4,5
The Epstein-Barr virus (EBV) is an ubiquitous
virus that is usually asymptomatic in young chil-
dren, although it is the primary cause of infectious
mononucleosis in some older children and young
adults. The seroprevalence of EBV is known to
differ among developed countries. In Japan as
well as in Korea most children by five years of age
are considered to be infected and seroconverted to
EBV.
6,7 Furthermore, EBV is associated with some
immunological disorders such as hemophagocytic
syndrome, lymphoproliferative disorders (e.g.,
Duncan Syndrome) and Burkitt's Lymphoma.
8
The EBV also has the characteristics of a latent
infection as one of the human herpes viruses, and
sometimes provokes reactivation.
There have been several studies on the relation-
ship between KD an EBV. Several studies in Japan
have reported that the prevalence of the EBV
antibody in KD patients and in children with a
past history of KD is significantly lower than that
of age-matched control children.
9-13 However,
other studies including a serologic study have
reported that EBV is not the pathologic agent of
KD.
14,15 The purpose of this study was to evaluate
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the relationship between KD and the atypical
presentation of an EBV infection.
MATERIALS AND METHODS
We performed three examinations in this study.
In the first examination, the subjects were 29 chil-
dren who had been diagnosed with KD (17 boys).
All the children met the criteria for KD and were
treated with intravenous immunoglobulin (IVIG)
at a dose of 2 g/kg over 12 hours and with aspirin
(30-40 mg/kg) during the febrile period. For coro-
nary artery lesions (CAL), echocardiography was
performed within two weeks of the onset of the
illness, during the fourth week, and then repeated
depending on the initial findings. There were five
children with CAL (17.2%) but none had a giant
aneurysm. The mean age of the patients was 2.1
± 1.1 years, with a range from 4 months-5 years.
After obtaining parental consent, serial sera were
collected from the patients at five different intervals
as follows: before, 1-2 weeks after, 1-2 months
after, 6 months after and 1 year after IVIG treat-
ment. Thirty-four healthy children of the same
ages (mean age 2.2 ± 1.0 years, 6 months-5 years)
were used as the control group. In the second ex-
amination, a serologic study of other herpes
viruses including the herpes simplex virus (HSV),
the varicella-zoster virus (VZV), and the cyto-
megalovirus (CMV) were examined using the sera
from the KD patients at presentation. In the third
examination, the subjects were 14 children who
had experienced KD in the past at their mean age
of 2.8 ± 1.5 years. The mean age of the subjects at
presentation was 8.3 ± 2.7 years. Fifteen age-
matched healthy children with a mean age of 8.4
± 2.6 years were used as the control group. The
collected samples were frozen at -20 before
being examined for EBV antibodies. Measure-
ments of antibodies were done using commer-
cially available kits. Anti-viral capsid antigens IgG
and IgM (anti-VCA IgG and IgM) were examined
by indirect fluorescent antibody assay (Bion Enter-
prises Ltd., Park Ridge, IL, USA), the anti-diffuse
and restricted early antigen IgG (anti-EADR IgG)
was evaluated by immunofluorescence assay
(Granbio Inc., Temecula, CA, USA), and the anti-
EBV determined nuclear antigen IgG (anti-EBNA
IgG) was examined using an anticomplement
immunofluorescence test (Bion Enterprises Ltd.,
Park Ridge, IL, USA). Antibodies to CMV and
VZV (RADIM, Pormezia, Italy) and HSV (Nova
Tec Immunodiagnostica GmbH, Dietzenbach,
Germany) were measured by an enzyme-linked
immunosorbent assay. The Ethics Committee on
Clinical Research of The Catholic University of
Korea at Daejeon St. Mary's Hospital approved
this study.
Statistical analysis
To analyze the relationships between the KD
group and the control group, a chi-square test and
a Fischer's exact test were used (SPSS version
10.0). A p value of < 0.05 was considered statisti-
cally significant.
RESULTS
Sequential profiles of EBV antibodies in KD
patients
The seropositive rates of the anti-VCA IgG and
IgM antibodies in the 29 KD patients at presen-
tation were 41.4% (12/29) and 0% (0/29), respec-
tively. Seropositive rates of almost 100% of anti-
VCA IgG and anti-EBNA IgG were observed at
1-2 weeks and at 1-2 months after the IVIG treat-
ment due to the effect of the infused IVIG. During
one year, five seronegative anti-VCA IgG patients
converted to positive and one seropositive patient
converted to negative status. Only one patient
showed the anti-VCA IgM at 1-2 weeks. There
was no case of seroconversion from positive to
negative in the anti-VCA IgG except for one, an
anti-EADR IgG and anti-EBNA IgG. There was no
significant difference in the seropositive rates of
the EBV antibodies except for an anti-EBNA IgG
between the KD patients at presentation and the
controls (Table 1).
Seropositive rates of herpes viruses in KD patients
The seropositive rates of antibodies to EBV (41%
vs. 65%), CMV (45% vs. 59%), HSV (21% vs. 24%),Epstein-Barr Virus Antibodies in Kawasaki Disease
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and HZV (34% vs. 26%) were similar in the
patients and controls. In the controls, the preva-
lence of HSV and HZV was lower than that of
EBV and CMV (Table 2).
EBV antibodies in the children with a past
history of KD
Children with a past history of KD were less
likely to have anti-VCA IgG antibodies than the
controls (10/14 vs. 14/15), but the difference was
not statistically significant. There was a difference
in the rates of anti-EADR IgG positive patients
(8/14, 57% vs. 3/15, 20%, p = 0.04) between the
groups, and there was also a more significant
difference when the subjects and controls that
were anti-VCA IgG-positive were selected (8/10,
80% vs. 3/14, 21%, p = 0.01, Table 3).
DISCUSSION
EBV has been an attractive candidate as the pri-
mary agent of KD for several reasons. However,
Table 1. Sequential Seropositivity for Epstein-Barr Virus Antibodies in Kawasaki Disease (KD) Patients after Intravenous




KD patients (n = 29)*
Controls (n = 34) p value
1-2 wk 1-2 mo 6 mo 1 yr
Anti-VCA IgG 12 (41) 29 (100) 29 (100) 21 (72) 16 (55) 22 (65) 0.06/0.44
Anti-VCA IgM 0 1 0 0 0 0
Anti-EADR IgG 8 (28) 13 (45) 15 (52) 16 (55) 13 (45) 16 (47) 0.11/0.86
Anti-EBNA IgG 5 (17) 26 (90) 28 (97) 10 (34) 8 (28) 14 (41) 0.04/0.26
* The same numbers of samples were collected serially five times before and after intravenous immunoglobulin treatment.
Comparison between KD patients before and one year after intravenous immunoglobulin treatment, and controls.
VCA, viral capsid antigen; EADR, diffuse and restricted early antigen; EBNA, EBV determined nuclear antigen.
Table 2. Seropositivity for Herpes Viruses Antibodies in Kawasaki Disease (KD) Patients and in Controls
Herpes viruses KD Patients (n = 29)* Controls (n = 34) p value
Anti-VCA IgG 12 (41%) 22 (65%) 0.06
Anti-CMV IgG 13 (45%) 20 (59%) 0.27
Anti-HSV IgG 6 (21%) 8 (24%) 0.79
Anti-HZV IgG 10 (34%) 9 (26%) 0.49
*Samples were collected before intravenous immunoglobulin treatment.
VCA, viral capsid antigen; CMV, cytomegalovirus; HSV, herpes simplex virus; HZV, herpes zoster virus.
Table 3. Epstein-Barr Virus Antibodies in Children with a Past History of Kawasaki Disease (KD) and in Controls
KD Patients (n = 14) Controls (n = 15) p value
Anti-VCA IgG 10 (71%) 14 (93%) 0.17
Anti-VCA IgM 0 0
Anti-EADR IgG 8 (57%) 3 (20%) 0.04
Anti-EBNA IgG 9 (64%) 14 (93%) 0.08
VCA, viral capsid antigen; EADR, diffuse and restricted early antigen; EBNA, EBV determined nuclear antigen.Soon-Ju Lee, et al.
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results of studies on KD and EBV have had some
limitations. Iwanaga et al. first suggested that an
abnormal immune response to the EBV may be
responsible for KD.
9 They found that only two out
of 69 (3%) KD patients were EBV seropositive. In
sharp contrast, 84% of the age- and sex-matched
controls were seropositive. Since the publication
of this report, several studies have produced simi-
lar results in Japan.
10-13 One study reported that
more than 80% of 57 KD patients showed sero-
logic evidence of a primary EBV infection within
one month of the illness as measured by a sensi-
tive anti-complement immunofluoresence test.
The serologic response to the EBV was signifi-
cantly low and transient, and it disappeared 1-2
weeks after the initial detection.
13 In addition,
Okano et al.
11 reported that 14 of 34 (41%) chil-
dren with a past history of KD (with a mean age
of 8.1 years) and 73 out of 88 (83%) of age- and
sex-matched controls were seropositive for the
EBV. In contrast, Marchette et al.
14 discovered that
61 of 278 (22%) KD patients (at a mean age of 28
months) and 110 of 242 (45%) controls (with a
mean age of 44 months) were anti-VCA IgG-posi-
tive (p < 0.01). However, there was no difference
in prevalence when partitioning according to age
and ethnicity. These studies indirectly indicate
that EBV seroprevalence in children is different in
Japan and in Hawaii.
In order to evaluate whether the seropositivity
of the EBV antibodies changes, we used the serial
sera of KD patients. Because the prevalence of
EBV is closely related to age, we carefully selected
the same-aged controls. Since all KD patients were
treated with IVIG (2 g/kg), the data at 1-2 weeks,
1-2 months, and 6 months were not reliable for
interpreting the EBV antibodies except for data
concerning anti-VCA IgM. We found that after
receiving IVIG (2 g/kg) the antibodies contained
in the IVIG (anti-hepatitis A IgG) could be de-
tected in approximately 30% of KD patients at 6
months and in 0% of the patients at 1 year (un-
published observation). We could not identify any
patients except for one who was anti-VCA IgM-
positive in the acute stage (within 1-2 weeks). One
child who was anti-VCA IgM-positive at one
week seroconverted to anti-VCA IgG- and anti-
EADR-positive after one year. While five anti-
VCA IgG-negative patients seroconverted to posi-
tive after one year, only one anti-VCA IgG-posi-
tive child seroconverted to negative after one
year. However, considering the child's age of six
months, this conversion may be the result of ma-
ternal antibodies. In this study, there was no dif-
ference in the anti-VCA IgG seropositivity between
KD patients and age-matched controls. EBNA
antibodies are known to appear after the anti-
VCA IgG is detected, and they persist for life. In
this study, there was a difference in the anti-
EBNA IgG seropositivity between KD patients
and controls (17% vs. 41%, p = 0.04, Table 1).
However, when the patients and controls with
anti-VCA IgG positive status were selected (5/12,
42% vs. 14/22, 64%, p = 0.22), there was no differ-
ence. These findings suggest that KD patients
experience normal immune responses to the EBV.
In keeping with previous studies,
12,14 we did not
find any differences in seropositivity to HSV,
HZV and CMV (Table 2). EADR antibodies are
detected after anti-VCA IgM and IgG antibodies
appear, and they disappear within 6 months to 2-3
years after initial infection. The earlier finding of
a lower anti-EBV-positive rate
11 and our finding of
a higher anti-EADR-positive rate suggest that
children who have recovered from KD are
infected with EBV later than other children of the
same age. This finding may be affected by the
immunological changes that occur after KD or
IVIG treatment. Another postulation is that the
humoral immunity caused by an unknown agent
that is partly related to EBV may protect the
children from EBV infection to some extent.
In conclusion, our results indicate that children
with KD have normal immune responses to an
EBV infection. Children with a past history of KD
seem to be infected with EBV later than normal
children of the same age.
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